Evidence Does Not Support Estrogen Therapy for Menopausal Hair Loss, Suggests Study
USA: A systematic review published in the Journal of the American Academy of Dermatology has revealed insufficient evidence to support the use of either topical estrogen or systemic menopausal hormone therapy for treating hair loss in women undergoing menopause.
After reviewing 13 studies, researchers concluded that estrogen-based therapies did not demonstrate a consistent benefit in improving hair growth. In addition to the lack of proven efficacy, both topical and systemic estrogen therapies were associated with potential safety concerns. These findings suggest that estrogen therapy should not be routinely recommended for menopausal hair loss, highlighting the need for further research into safer and more effective treatment options.
Hair thinning is a common concern during menopause, but the effectiveness of estrogen therapy for treating it remains unclear. To assess the evidence, researchers conducted a PRISMA-guided systematic review of studies published through July 2025, searching PubMed, Embase, and Scopus. The Brief Report, published in the Journal of the American Academy of Dermatology, included peer-reviewed interventional and observational studies while excluding animal studies, case reports, and non-English publications.
Of the 1,715 records screened, only 13 studies met the inclusion criteria. Quality assessment using Critical Appraisal Skills Programme (CASP) checklists showed that most studies had moderate to substantial methodological limitations, weakening the overall strength of the evidence.
The key findings of the review included:
- Topical 17α-estradiol (0.025%–0.05%), the most extensively studied formulation, showed modest improvements in hair count and thickness in uncontrolled studies but was inferior to topical minoxidil in a randomized controlled trial.
- A combination of topical finasteride and minoxidil performed better than 17α-estradiol combined with minoxidil in women with female pattern hair loss.
- Combining 17α-ethinylestradiol with 2% minoxidil did not provide additional benefit over minoxidil alone and was associated with a higher rate of menstrual irregularities.
- A placebo-controlled trial of estradiol valerate (0.03%) reported improvements in hair growth cycles but also documented serious gynecologic adverse events, including one case of breast cancer and two cases of endometrial hyperplasia, although a direct causal relationship was not established.
- Evidence for systemic menopausal hormone therapy was inconsistent. While some studies reported subjective improvements in female pattern hair loss, others found an increased risk of frontal fibrosing alopecia, a form of scarring hair loss.
The review identified major evidence gaps, including the absence of studies evaluating topical 17β-estradiol, the estrogen formulation most commonly used in menopausal hormone therapy. Most included studies were small, had short follow-up, used varied treatment regimens, and reported inconsistent outcomes, limiting the strength of the evidence.
The authors concluded that current evidence does not support the routine use of topical estrogen or systemic menopausal hormone therapy for menopausal hair loss. They noted that topical minoxidil remains the only FDA-approved treatment for female pattern hair loss and called for robust clinical trials to establish the safety and efficacy of estrogen-based therapies.
Reference:
Farkas, E., Nehorayan, I., Hanan, R., Kalner, S., Tepper, K., & Marmon, S. (2026). Untangling estrogen therapy for menopausal hair loss: A systematic review. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2026.04.1924
Next Story